Page last updated: 2024-12-10

diosmetin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators
FloraRankFlora DefinitionFamilyFamily Definition
CitrusgenusA plant genus of the family RUTACEAE. They bear the familiar citrus fruits including oranges, grapefruit, lemons, and limes. There are many hybrids which makes the nomenclature confusing.[MeSH]RutaceaeA plant family in the order Sapindales that grows in warmer regions and has conspicuous flowers.[MeSH]

Cross-References

ID SourceID
PubMed CID5281612
CHEMBL ID90568
CHEBI ID4630
SCHEMBL ID289337
MeSH IDM0118511

Synonyms (95)

Synonym
CHEMBL90568
diosmetine
BRD-K26862302-001-02-9
DIVK1C_006531
KBIO1_001475
SDCCGMLS-0066783.P001
5,7-dihydroxy-2-(3-hydroxy-4-methoxy-phenyl)chromen-4-one
4h-1-benzopyran-4-one, 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-
SPECTRUM_001505
BSPBIO_002653
SPECTRUM5_001707
NCGC00178549-01
5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4h-1-benzopyran-4-one
5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4h-chromen-4-one
5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone
3',5,7-trihydroxy-4'-methoxyflavone
CHEBI:4630 ,
salinigricoflavonol
diosmetin ,
520-34-3
luteolin 4'-methyl ether
C10038
NCGC00163540-01
KBIO2_001985
KBIO2_007121
KBIOSS_001985
KBIOGR_001586
KBIO2_004553
KBIO3_001873
SPECPLUS_000435
SPECTRUM2_001638
SPBIO_001735
SPECTRUM4_001113
SPECTRUM3_000987
bdbm23414
3',5,7-trihydroxy-4'-methoxy flavone
luteolin 4-methyl ether
FT-0667618
5,7,3'-trihydroxy-4'-methoxyflavone
4'-methylluteolin
LMPK12110824
NCGC00163540-02
5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one
AKOS005720974
pillon
flavone, 3',5,7-trihydroxy-4'-methoxy-
twz37241ot ,
einecs 208-291-8
hsdb 8101
unii-twz37241ot
2-(4-methoxy-3-oxidanyl-phenyl)-5,7-bis(oxidanyl)chromen-4-one
5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-1-benzopyran-4-one
A828902
CCG-38758
STL146390
FT-0603442
NCGC00163540-03
cyanidenon-4'-methyl ether 1479
luteolin-4'-methyl ether
diosmetin [mi]
diosmetol
diosmetin [who-dd]
diosmetin [inci]
S2380
SCHEMBL289337
BBL027839
MBNGWHIJMBWFHU-UHFFFAOYSA-N
MLS006011843
smr002044787
mfcd00017425
HY-N0125
CS-5455
diosmetin, analytical standard
DTXSID80199966 ,
HMS3656G13
SR-05000002196-3
sr-05000002196
SR-05000002196-2
5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4h-1-benzopyran-4-one (diosmetin)
SW219332-1
DB11259
J8D ,
diosmetin (luteolin 4-methyl ether)
BS-17174
BCP28283
Q1649664
BRD-K26862302-001-03-7
SY066981
A871094
AC-34868
isaknox x202 whitening secret essence
isa knox wxii plus whitening revolution serum
whoo gongjinhyang seol whitening jin essence
dtxcid40122457
D4441

Research Excerpts

Overview

Diosmetin is a member of the flavonoid glycosides family, which suppresses the inflammatory response and cellular apoptosis and enhances antioxidant activity. It is a bioflavonoid with cytotoxicity properties against variety of cancer cells.

ExcerptReferenceRelevance
"Diosmetin is a bioflavonoid compound naturally abundant in citrus fruits. "( Diosmetin inhibits cell proliferation and promotes apoptosis through STAT3/c-Myc signaling pathway in human osteosarcoma cells.
Chen, G; Fang, R; Ning, R; Qian, F; Zhang, Y; Zhao, W, 2021
)
3.51
"Diosmetin (DIOS) is a functional compound with poor water solubility, bad permeability, and crystal form. "( Design, Characterization, and Evaluation of Diosmetin-Loaded Solid Self-microemulsifying Drug Delivery System Prepared by Electrospray for Improved Bioavailability.
Adu-Frimpong, M; Gu, Z; Li, S; Xu, X; Xu, Y; Xue, Y; Yu, J; Zhu, Y, 2022
)
2.43
"Diosmetin (DIO) is a natural flavonoid with antitumor effect."( Diosmetin inhibits the growth and invasion of gastric cancer by interfering with M2 phenotype macrophage polarization.
Luo, H; Zhang, F, 2023
)
3.07
"Diosmetin is a bioflavonoid possessing an anti-inflammatory property."( Diosmetin exhibits anti-proliferative and anti-inflammatory effects on TNF-α-stimulated human rheumatoid arthritis fibroblast-like synoviocytes through regulating the Akt and NF-κB signaling pathways.
Chen, Y; Liu, M; Wang, Y; Yang, G; Zhou, B, 2020
)
2.72
"Diosmetin is a flavonoid present naturally in citrus fruit. "( Mechanism underlying the vasodilation induced by diosmetin in porcine coronary artery.
Ahmad, T; Khan, T; Roberts, R; Shah, AJ, 2020
)
2.26
"Diosmetin is a member of the flavonoid glycosides family, which suppresses the inflammatory response and cellular apoptosis and enhances antioxidant activity."( Diosmetin protects against ischemia/reperfusion-induced acute kidney injury in mice.
Huang, WF; Li, WF; Yang, K; Yi, C; Yu, JF, 2017
)
2.62
"Diosmetin (DIO) is a natural flavonoid with properties of antioxidant, anti-infection, and antishock."( Diosmetin inhibits osteoclast formation and differentiation and prevents LPS-induced osteolysis in mice.
Ding, J; Fu, F; Li, C; Li, K; Lin, X; Liu, Q; Shao, S; Song, F; Su, Y; Wang, Z; Wu, ZX; Xiao, Y; Xu, J; Yuan, G; Zhao, J, 2019
)
2.68
"Diosmetin (Dis) is a bioflavonoid with cytotoxicity properties against variety of cancer cells including hepatocarcinoma, breast and colorectal (CRC) cancer. "( Investigation into the Molecular Mechanisms underlying the Anti-proliferative and Anti-tumorigenesis activities of Diosmetin against HCT-116 Human Colorectal Cancer.
Alshawsh, MA; Koosha, S; Mohamed, Z; Sinniah, A, 2019
)
2.17
"Diosmetin is a natural flavonoid obtained from citrus fruits and some medicinal herbs. "( Diosmetin inhibits tumor development and block tumor angiogenesis in skin cancer.
Choi, J; Lee, DH; Park, SY; Seol, JW, 2019
)
3.4
"Diosmetin (DIOS) is a flavone aglycone commonly occurring in citrus species and olive leaves, in addition it is one of the active ingredients of some medications. "( Flavonoid diosmetin increases ATP levels in kidney cells and relieves ATP depleting effect of ochratoxin A.
Antus, C; Jakus, PB; Kőszegi, T; Montskó, G; Petrik, J; Poór, M; Veres, B; Vladimir-Knežević, S; Zrínyi, Z, 2014
)
2.25
"Diosmetin (Dio) is a major active component of flavonoid compounds. "( Diosmetin induces apoptosis by upregulating p53 via the TGF-β signal pathway in HepG2 hepatoma cells.
Chen, N; Liu, B; Liu, J; Peng, W; Shi, Y; Zhang, Q; Zhu, R, 2016
)
3.32

Effects

Diosmetin has shown great potential in the control of several diseases. It has significant potential as a therapeutic intervention to ameliorate renal injury after renal I/R.

ExcerptReferenceRelevance
"Diosmetin has shown great potential in the control of several diseases. "( Diosmetin alleviates hypoxia‑induced myocardial apoptosis by inducing autophagy through AMPK activation.
Huang, D; Shi, Y; Si, Q; Zhang, N, 2020
)
3.44
"Diosmetin has significant potential as a therapeutic intervention to ameliorate renal injury after renal I/R."( Diosmetin protects against ischemia/reperfusion-induced acute kidney injury in mice.
Huang, WF; Li, WF; Yang, K; Yi, C; Yu, JF, 2017
)
2.62
"Diosmetin has anticancer, antioxidant and blood lipid lowering activities."( Simultaneous Determination and Quantitation of Diosmetin and Hesperetin in Human Plasma by Liquid Chromatographic Mass Spectrometry With an Application to Pharmacokinetic Studies.
Chakraborty, S; Dan, S; Ghosh, B; Khanam, J; Mandal, P; Pal, TK; Saha, C, 2019
)
1.49

Treatment

Diosmetin significantly reduced the dermatitis score, thickness of epidermis and dermis and number of mast cells in comparison with the untreated group. Treatment with diosmetin also delayed tumor growth in AML mouse xenografts.

ExcerptReferenceRelevance
"Diosmetin treatment resulted in an increase in apoptotic rates and a reduction in TNF-α-induced production of IL-1β, IL-6, IL-8, and MMP-1 in MH7A cells."( Diosmetin exhibits anti-proliferative and anti-inflammatory effects on TNF-α-stimulated human rheumatoid arthritis fibroblast-like synoviocytes through regulating the Akt and NF-κB signaling pathways.
Chen, Y; Liu, M; Wang, Y; Yang, G; Zhou, B, 2020
)
2.72
"Treatment with diosmetin significantly reduced the dermatitis score, thickness of epidermis and dermis and number of mast cells in comparison with the untreated group."( Anti-inflammatory effects of natural flavonoid diosmetin in IL-4 and LPS-induced macrophage activation and atopic dermatitis model.
Choi, J; Jang, H; Lee, DH; Park, JK; Seol, JW, 2020
)
1.15
"Treatment with diosmetin also delayed tumor growth in AML mouse xenografts."( Diosmetin Induces Apoptosis of Acute Myeloid Leukemia Cells.
Roma, A; Rota, SG; Spagnuolo, PA, 2018
)
2.26
"Treatment with diosmetin attenuated the altered level of oxidative stress parameters and inflammatory cytokines in the STZ-induced DN mice."( Diosmetin Attenuates Akt Signaling Pathway by Modulating Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB)/Inducible Nitric Oxide Synthase (iNOS) in Streptozotocin (STZ)-Induced Diabetic Nephropathy Mice.
Jiang, Y; Liu, C; Liu, J; Liu, K; Zhou, Z, 2018
)
2.26
"Cotreatments of diosmetin and betaine showed the most robust additive effects, as confirmed by three independent functional assays in primary PEX1-G843D patient cells, but neither agent was active alone or in combination in patient cells homozygous for the PEX1 c.2097_2098insT null allele."( Zellweger spectrum disorder patient-derived fibroblasts with the PEX1-Gly843Asp allele recover peroxisome functions in response to flavonoids.
Argyriou, C; Birjandian, S; Braverman, NE; Di Pietro, E; Hacia, JG; MacLean, GE; Saberian, P; Sun, X, 2019
)
0.85
"Pretreatment with diosmetin significantly reduced serum levels of amylase and lipase; the histological injury; the secretion of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6; myeloperoxidase (MPO) activity, trypsinogen activation peptide (TAP) level, the expression of inducible nitric oxide synthase (iNOS); and the nuclear factor (NF)-κB activation in cerulein-induced AP."( Diosmetin ameliorates the severity of cerulein-induced acute pancreatitis in mice by inhibiting the activation of the nuclear factor-κB.
Cang, X; Fan, Y; Hu, G; Hu, Y; Qiu, L; Wan, R; Wang, X; Xiao, W; Xing, M; Xiong, J; Yin, G; Yu, G, 2014
)
2.17

Pharmacokinetics

ExcerptReferenceRelevance
" Analysis of the pharmacokinetic parameters showed that the drug was rapidly absorbed."( Pharmacokinetics and metabolism of oral diosmin in healthy volunteers.
Cova, D; De Angelis, L; Giavarini, F; Palladini, G; Perego, R, 1992
)
0.28
" Finally, the method was successfully applied to the pharmacokinetic study of diosmin in healthy volunteers following a single oral administration (Daflon)."( Simultaneous determination of diosmin and diosmetin in human plasma by ion trap liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry: Application to a clinical pharmacokinetic study.
Azanza, JR; Campanero, MA; Escolar, M; Garcia-Quetglas, E; Perez, G; Sadaba, B, 2010
)
0.62
" The aim of the current in vivo study was to investigate the pharmacokinetic profile of a branded micronized diosmin (µSMIN Plus™) compared with plain micronized diosmin in male Sprague-Dawley rats."( Pharmacokinetic Profile of µSMIN Plus™, a new Micronized Diosmin Formulation, after Oral Administration in Rats.
Ciccone, M; Mancinelli, A; Pisano, C; Russo, R; Severino, L; Terruzzi, F, 2015
)
0.42
" In the present study efforts were given to develop and validate a bioanalytical method for simultaneous estimation of diosmetin and hesperitin in human plasma by liquid chromatography electron spray ionization mass spectrometry with an application to the analysis of plasma samples obtained from the comparative pharmacokinetic studies on healthy human volunteers under the framework of bioequivalence study."( Simultaneous Determination and Quantitation of Diosmetin and Hesperetin in Human Plasma by Liquid Chromatographic Mass Spectrometry With an Application to Pharmacokinetic Studies.
Chakraborty, S; Dan, S; Ghosh, B; Khanam, J; Mandal, P; Pal, TK; Saha, C, 2019
)
0.98

Bioavailability

ExcerptReferenceRelevance
" Thus, this work brings evidence that diosmetin is rapidly glucuronoconjugated in the rat and provides an explanation for the low po bioavailability of the unchanged compound that can be generalized to this important class of natural compounds."( In vivo and in vitro glucuronidation of the flavonoid diosmetin in rats.
Bertin, D; Boutin, JA; Hennig, P; Lambert, PH; Meunier, F; Serkiz, B; Volland, JP,
)
0.65
" For each animal, the following pharmacokinetic parameters were calculated using a non-compartmental analysis: maximum plasma drug concentration (Cmax), time to reach Cmax (Tmax), area under the plasma concentration-time curve (AUC0-last), elimination half-life (t½), and relative oral bioavailability (%F)."( Pharmacokinetic Profile of µSMIN Plus™, a new Micronized Diosmin Formulation, after Oral Administration in Rats.
Ciccone, M; Mancinelli, A; Pisano, C; Russo, R; Severino, L; Terruzzi, F, 2015
)
0.42
" On the basis of comparison of the AUC0-t, the relative bioavailability of the test preparation was found 100."( Simultaneous Determination and Quantitation of Diosmetin and Hesperetin in Human Plasma by Liquid Chromatographic Mass Spectrometry With an Application to Pharmacokinetic Studies.
Chakraborty, S; Dan, S; Ghosh, B; Khanam, J; Mandal, P; Pal, TK; Saha, C, 2019
)
0.77
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Therefore, the oral bioavailability of DIOS improved significantly compared with liquid SMEDDS (4."( Design, Characterization, and Evaluation of Diosmetin-Loaded Solid Self-microemulsifying Drug Delivery System Prepared by Electrospray for Improved Bioavailability.
Adu-Frimpong, M; Gu, Z; Li, S; Xu, X; Xu, Y; Xue, Y; Yu, J; Zhu, Y, 2022
)
0.98

Dosage Studied

ExcerptRelevanceReference
" For the in vivo study, healthy male Sprague Dawley rats were consecutively administered acacetin or apigenin for 7 days at the dosage of 5 mg/kg after being randomly divided into 3 groups: Group A (control group), Group B (acacetin group) and Group C (apigenin group)."( Inhibitory Effect of
Chen, F; Geng, P; Hua, A; Wang, S; Wen, C; Yan, L; Zhou, Q; Zhou, Y, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (10)

RoleDescription
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
tropomyosin-related kinase B receptor agonistAn agonist that binds to and deactivates the tropomyosin-related kinase B (TrkB) receptor, the main signaling receptor of the neurotrophin brain-derived neurotrophic factor (BDNF).
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
angiogenesis inhibitorAn agent and endogenous substances that antagonize or inhibit the development of new blood vessels.
cardioprotective agentAny protective agent that is able to prevent damage to the heart.
bone density conservation agentAn agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
vasodilator agentA drug used to cause dilation of the blood vessels.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
monomethoxyflavoneAny methoxyflavone with a single methoxy substituent.
trihydroxyflavoneAny hydroxyflavone carrying three hydroxy groups at unspecified positions.
3'-hydroxyflavonoidAny hydroxyflavone with a hydroxy substituent at position 3'.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency12.58930.003245.467312,589.2998AID2517
PPM1D proteinHomo sapiens (human)Potency11.70860.00529.466132.9993AID1347411
EWS/FLI fusion proteinHomo sapiens (human)Potency10.65790.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
Interferon betaHomo sapiens (human)Potency11.70860.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lysine-specific histone demethylase 1AHomo sapiens (human)IC50 (µMol)27.90000.00312.16029.6000AID1515260
Cytochrome P450 1A1Homo sapiens (human)IC50 (µMol)0.14000.00791.24789.9000AID502474
Cytochrome P450 1A1Homo sapiens (human)Ki0.08900.01200.94693.8000AID598341
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)2.43700.00011.774010.0000AID502473
Multidrug resistance-associated protein 1 Homo sapiens (human)IC50 (µMol)3.00000.00153.71109.6600AID427749
Mitogen-activated protein kinase 10Homo sapiens (human)IC50 (µMol)25.90000.00201.703510.0000AID1799639
Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)25.90000.00010.72667.8000AID1799639
Cytochrome P450 1B1Homo sapiens (human)IC50 (µMol)0.02900.00130.86969.9000AID502475
Cytochrome P450 1B1Homo sapiens (human)Ki0.01600.00300.97417.4600AID1452994; AID598342
Inositol polyphosphate multikinaseHomo sapiens (human)IC50 (µMol)7.20001.10003.78337.2000AID1572025
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)50.00002.41006.343310.0000AID427750
Aurora kinase BHomo sapiens (human)IC50 (µMol)3.86000.00030.96349.8000AID1801097
Inositol hexakisphosphate kinase 2Homo sapiens (human)IC50 (µMol)0.90000.50002.35567.1000AID1572024
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Catechol O-methyltransferaseRattus norvegicus (Norway rat)Km3.24002.38002.94754.1000AID1216717; AID1216719
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (297)

Processvia Protein(s)Taxonomy
regulation of double-strand break repair via homologous recombinationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of protein ubiquitinationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of protein localizationLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to UVLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to gamma radiationLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair-dependent chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuroblast proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
protein demethylationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of epithelial to mesenchymal transitionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuron projection developmentLysine-specific histone demethylase 1AHomo sapiens (human)
cerebral cortex developmentLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
neuron maturationLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cell sizeLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-templated transcriptionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
guanine metabolic processLysine-specific histone demethylase 1AHomo sapiens (human)
muscle cell developmentLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of androgen receptor signaling pathwayLysine-specific histone demethylase 1AHomo sapiens (human)
response to fungicideLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to cAMPLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of DNA methylation-dependent heterochromatin formationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cold-induced thermogenesisLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neural precursor cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of stem cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1A1Homo sapiens (human)
response to hypoxiaCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
lipid hydroxylationCytochrome P450 1A1Homo sapiens (human)
fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid metabolic processCytochrome P450 1A1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A1Homo sapiens (human)
amine metabolic processCytochrome P450 1A1Homo sapiens (human)
response to nematodeCytochrome P450 1A1Homo sapiens (human)
response to herbicideCytochrome P450 1A1Homo sapiens (human)
ethylene metabolic processCytochrome P450 1A1Homo sapiens (human)
coumarin metabolic processCytochrome P450 1A1Homo sapiens (human)
flavonoid metabolic processCytochrome P450 1A1Homo sapiens (human)
response to iron(III) ionCytochrome P450 1A1Homo sapiens (human)
insecticide metabolic processCytochrome P450 1A1Homo sapiens (human)
dibenzo-p-dioxin catabolic processCytochrome P450 1A1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
response to foodCytochrome P450 1A1Homo sapiens (human)
response to lipopolysaccharideCytochrome P450 1A1Homo sapiens (human)
response to vitamin ACytochrome P450 1A1Homo sapiens (human)
response to immobilization stressCytochrome P450 1A1Homo sapiens (human)
vitamin D metabolic processCytochrome P450 1A1Homo sapiens (human)
retinol metabolic processCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
9-cis-retinoic acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
camera-type eye developmentCytochrome P450 1A1Homo sapiens (human)
nitric oxide metabolic processCytochrome P450 1A1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1A1Homo sapiens (human)
digestive tract developmentCytochrome P450 1A1Homo sapiens (human)
tissue remodelingCytochrome P450 1A1Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A1Homo sapiens (human)
response to hyperoxiaCytochrome P450 1A1Homo sapiens (human)
maternal process involved in parturitionCytochrome P450 1A1Homo sapiens (human)
hepatocyte differentiationCytochrome P450 1A1Homo sapiens (human)
cellular response to copper ionCytochrome P450 1A1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleCytochrome P450 1A1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1A1Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
leukotriene metabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
response to xenobiotic stimulusMultidrug resistance-associated protein 1 Homo sapiens (human)
cobalamin transportMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid biosynthetic processMultidrug resistance-associated protein 1 Homo sapiens (human)
cellular response to oxidative stressMultidrug resistance-associated protein 1 Homo sapiens (human)
heme catabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transportMultidrug resistance-associated protein 1 Homo sapiens (human)
phospholipid translocationMultidrug resistance-associated protein 1 Homo sapiens (human)
positive regulation of inflammatory responseMultidrug resistance-associated protein 1 Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
cell chemotaxisMultidrug resistance-associated protein 1 Homo sapiens (human)
transepithelial transportMultidrug resistance-associated protein 1 Homo sapiens (human)
cyclic nucleotide transportMultidrug resistance-associated protein 1 Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 1 Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid translocationMultidrug resistance-associated protein 1 Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 1 Homo sapiens (human)
cellular response to amyloid-betaMultidrug resistance-associated protein 1 Homo sapiens (human)
carboxylic acid transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierMultidrug resistance-associated protein 1 Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 10Homo sapiens (human)
signal transductionMitogen-activated protein kinase 10Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase 10Homo sapiens (human)
response to light stimulusMitogen-activated protein kinase 10Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase 10Homo sapiens (human)
regulation of circadian rhythmMitogen-activated protein kinase 10Homo sapiens (human)
rhythmic processMitogen-activated protein kinase 10Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 10Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipopolysaccharideMitogen-activated protein kinase 14Homo sapiens (human)
DNA damage checkpoint signalingMitogen-activated protein kinase 14Homo sapiens (human)
cell morphogenesisMitogen-activated protein kinase 14Homo sapiens (human)
cartilage condensationMitogen-activated protein kinase 14Homo sapiens (human)
angiogenesisMitogen-activated protein kinase 14Homo sapiens (human)
osteoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
placenta developmentMitogen-activated protein kinase 14Homo sapiens (human)
response to dietary excessMitogen-activated protein kinase 14Homo sapiens (human)
chondrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusMitogen-activated protein kinase 14Homo sapiens (human)
glucose metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 14Homo sapiens (human)
chemotaxisMitogen-activated protein kinase 14Homo sapiens (human)
signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
skeletal muscle tissue developmentMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myotube differentiationMitogen-activated protein kinase 14Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 14Homo sapiens (human)
fatty acid oxidationMitogen-activated protein kinase 14Homo sapiens (human)
platelet activationMitogen-activated protein kinase 14Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 14Homo sapiens (human)
osteoclast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 14Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
response to muramyl dipeptideMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of interleukin-12 productionMitogen-activated protein kinase 14Homo sapiens (human)
response to insulinMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of hippo signalingMitogen-activated protein kinase 14Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusMitogen-activated protein kinase 14Homo sapiens (human)
response to muscle stretchMitogen-activated protein kinase 14Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of protein import into nucleusMitogen-activated protein kinase 14Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of erythrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
glucose importMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of glucose importMitogen-activated protein kinase 14Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
stem cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
striated muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationMitogen-activated protein kinase 14Homo sapiens (human)
bone developmentMitogen-activated protein kinase 14Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipoteichoic acidMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to ionizing radiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of brown fat cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 14Homo sapiens (human)
stress-induced premature senescenceMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to virusMitogen-activated protein kinase 14Homo sapiens (human)
regulation of synaptic membrane adhesionMitogen-activated protein kinase 14Homo sapiens (human)
regulation of cytokine production involved in inflammatory responseMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast fusionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1B1Homo sapiens (human)
angiogenesisCytochrome P450 1B1Homo sapiens (human)
trabecular meshwork developmentCytochrome P450 1B1Homo sapiens (human)
DNA modificationCytochrome P450 1B1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1B1Homo sapiens (human)
nitric oxide biosynthetic processCytochrome P450 1B1Homo sapiens (human)
cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to nutrientCytochrome P450 1B1Homo sapiens (human)
steroid metabolic processCytochrome P450 1B1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell population proliferationCytochrome P450 1B1Homo sapiens (human)
male gonad developmentCytochrome P450 1B1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressCytochrome P450 1B1Homo sapiens (human)
toxin metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionCytochrome P450 1B1Homo sapiens (human)
positive regulation of smooth muscle cell migrationCytochrome P450 1B1Homo sapiens (human)
sterol metabolic processCytochrome P450 1B1Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 1B1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
collagen fibril organizationCytochrome P450 1B1Homo sapiens (human)
adrenal gland developmentCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell migrationCytochrome P450 1B1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityCytochrome P450 1B1Homo sapiens (human)
response to follicle-stimulating hormoneCytochrome P450 1B1Homo sapiens (human)
response to estradiolCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinCytochrome P450 1B1Homo sapiens (human)
benzene-containing compound metabolic processCytochrome P450 1B1Homo sapiens (human)
retinol metabolic processCytochrome P450 1B1Homo sapiens (human)
retinal metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of apoptotic processCytochrome P450 1B1Homo sapiens (human)
blood vessel endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
estrous cycleCytochrome P450 1B1Homo sapiens (human)
positive regulation of translationCytochrome P450 1B1Homo sapiens (human)
positive regulation of angiogenesisCytochrome P450 1B1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCytochrome P450 1B1Homo sapiens (human)
membrane lipid catabolic processCytochrome P450 1B1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1B1Homo sapiens (human)
blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
retinal blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
ganglion developmentCytochrome P450 1B1Homo sapiens (human)
cellular response to hydrogen peroxideCytochrome P450 1B1Homo sapiens (human)
cellular response to cAMPCytochrome P450 1B1Homo sapiens (human)
cellular response to tumor necrosis factorCytochrome P450 1B1Homo sapiens (human)
cellular response to luteinizing hormone stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to cortisol stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to progesterone stimulusCytochrome P450 1B1Homo sapiens (human)
response to dexamethasoneCytochrome P450 1B1Homo sapiens (human)
endothelial cell-cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to indole-3-methanolCytochrome P450 1B1Homo sapiens (human)
cellular response to toxic substanceCytochrome P450 1B1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1B1Homo sapiens (human)
regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of DNA biosynthetic processCytochrome P450 1B1Homo sapiens (human)
inositol trisphosphate metabolic processInositol polyphosphate multikinaseHomo sapiens (human)
inositol phosphate metabolic processInositol polyphosphate multikinaseHomo sapiens (human)
phosphatidylinositol metabolic processInositol polyphosphate multikinaseHomo sapiens (human)
necroptotic processInositol polyphosphate multikinaseHomo sapiens (human)
inositol phosphate biosynthetic processInositol polyphosphate multikinaseHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIAurora kinase BHomo sapiens (human)
mitotic cell cycleAurora kinase BHomo sapiens (human)
mitotic cytokinesisAurora kinase BHomo sapiens (human)
negative regulation of B cell apoptotic processAurora kinase BHomo sapiens (human)
protein phosphorylationAurora kinase BHomo sapiens (human)
spindle organizationAurora kinase BHomo sapiens (human)
attachment of spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
abscissionAurora kinase BHomo sapiens (human)
negative regulation of protein bindingAurora kinase BHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseAurora kinase BHomo sapiens (human)
negative regulation of cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of cytokinesisAurora kinase BHomo sapiens (human)
protein localization to kinetochoreAurora kinase BHomo sapiens (human)
cellular response to UVAurora kinase BHomo sapiens (human)
cleavage furrow formationAurora kinase BHomo sapiens (human)
post-translational protein modificationAurora kinase BHomo sapiens (human)
cell cycle G2/M phase transitionAurora kinase BHomo sapiens (human)
mitotic cytokinesis checkpoint signalingAurora kinase BHomo sapiens (human)
negative regulation of innate immune responseAurora kinase BHomo sapiens (human)
protein autophosphorylationAurora kinase BHomo sapiens (human)
mitotic spindle midzone assemblyAurora kinase BHomo sapiens (human)
positive regulation of telomerase activityAurora kinase BHomo sapiens (human)
regulation of chromosome segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic cell cycle spindle assembly checkpointAurora kinase BHomo sapiens (human)
mitotic spindle assemblyAurora kinase BHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayAurora kinase BHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid separationAurora kinase BHomo sapiens (human)
positive regulation of attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
positive regulation of mitotic cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of telomere cappingAurora kinase BHomo sapiens (human)
positive regulation of lateral attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
mitotic spindle organizationAurora kinase BHomo sapiens (human)
regulation of cytokinesisAurora kinase BHomo sapiens (human)
negative regulation of cell growthInositol hexakisphosphate kinase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationInositol hexakisphosphate kinase 2Homo sapiens (human)
positive regulation of apoptotic processInositol hexakisphosphate kinase 2Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 2Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 2Homo sapiens (human)
protein stabilizationInositol hexakisphosphate kinase 2Homo sapiens (human)
cellular response to flavonoidInositol hexakisphosphate kinase 2Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (88)

Processvia Protein(s)Taxonomy
telomeric DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
p53 bindingLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
oxidoreductase activityLysine-specific histone demethylase 1AHomo sapiens (human)
enzyme bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear receptor coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K4 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
identical protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
MRF bindingLysine-specific histone demethylase 1AHomo sapiens (human)
flavin adenine dinucleotide bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear androgen receptor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
telomeric repeat-containing RNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
FAD-dependent H3K4me/H3K4me3 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
promoter-specific chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
iron ion bindingCytochrome P450 1A1Homo sapiens (human)
protein bindingCytochrome P450 1A1Homo sapiens (human)
arachidonic acid monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activity, acting on diphenols and related substances as donorsCytochrome P450 1A1Homo sapiens (human)
flavonoid 3'-monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxygen bindingCytochrome P450 1A1Homo sapiens (human)
enzyme bindingCytochrome P450 1A1Homo sapiens (human)
heme bindingCytochrome P450 1A1Homo sapiens (human)
Hsp70 protein bindingCytochrome P450 1A1Homo sapiens (human)
demethylase activityCytochrome P450 1A1Homo sapiens (human)
Hsp90 protein bindingCytochrome P450 1A1Homo sapiens (human)
aromatase activityCytochrome P450 1A1Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type vitamin B12 transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled lipid transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
carboxylic acid transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
JUN kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
protein bindingMitogen-activated protein kinase 10Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 10Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 14Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase 14Homo sapiens (human)
mitogen-activated protein kinase p38 bindingMitogen-activated protein kinase 14Homo sapiens (human)
NFAT protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
monooxygenase activityCytochrome P450 1B1Homo sapiens (human)
iron ion bindingCytochrome P450 1B1Homo sapiens (human)
protein bindingCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
heme bindingCytochrome P450 1B1Homo sapiens (human)
aromatase activityCytochrome P450 1B1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1B1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
inositol-1,4,5-trisphosphate 6-kinase activityInositol polyphosphate multikinaseHomo sapiens (human)
inositol tetrakisphosphate 3-kinase activityInositol polyphosphate multikinaseHomo sapiens (human)
inositol tetrakisphosphate 6-kinase activityInositol polyphosphate multikinaseHomo sapiens (human)
protein bindingInositol polyphosphate multikinaseHomo sapiens (human)
ATP bindingInositol polyphosphate multikinaseHomo sapiens (human)
inositol-1,4,5-trisphosphate 3-kinase activityInositol polyphosphate multikinaseHomo sapiens (human)
metal ion bindingInositol polyphosphate multikinaseHomo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activityInositol polyphosphate multikinaseHomo sapiens (human)
inositol tetrakisphosphate 5-kinase activityInositol polyphosphate multikinaseHomo sapiens (human)
flavonoid bindingInositol polyphosphate multikinaseHomo sapiens (human)
myo-inositol-1,2,3,4,6-heptakisphosphate 5-kinase activityInositol polyphosphate multikinaseHomo sapiens (human)
inositol tetrakisphosphate kinase activityInositol polyphosphate multikinaseHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase BHomo sapiens (human)
protein bindingAurora kinase BHomo sapiens (human)
ATP bindingAurora kinase BHomo sapiens (human)
kinase bindingAurora kinase BHomo sapiens (human)
protein serine kinase activityAurora kinase BHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 2Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 2Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 2Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 2Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 2Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 2Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 2Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 2Homo sapiens (human)
flavonoid bindingInositol hexakisphosphate kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (43)

Processvia Protein(s)Taxonomy
chromatinLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
chromosome, telomeric regionLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
nucleoplasmLysine-specific histone demethylase 1AHomo sapiens (human)
transcription regulator complexLysine-specific histone demethylase 1AHomo sapiens (human)
protein-containing complexLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair complexLysine-specific histone demethylase 1AHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 1A1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
basal plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
lateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
extracellular exosomeMultidrug resistance-associated protein 1 Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 10Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 10Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 10Homo sapiens (human)
cytosolMitogen-activated protein kinase 10Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 10Homo sapiens (human)
nucleusMitogen-activated protein kinase 10Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 10Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
spindle poleMitogen-activated protein kinase 14Homo sapiens (human)
extracellular regionMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 14Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
nuclear speckMitogen-activated protein kinase 14Homo sapiens (human)
secretory granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
glutamatergic synapseMitogen-activated protein kinase 14Homo sapiens (human)
ficolin-1-rich granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
mitochondrionCytochrome P450 1B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1B1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1B1Homo sapiens (human)
nucleoplasmInositol polyphosphate multikinaseHomo sapiens (human)
nucleusInositol polyphosphate multikinaseHomo sapiens (human)
cytoplasmInositol polyphosphate multikinaseHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
condensed chromosome, centromeric regionAurora kinase BHomo sapiens (human)
nucleusAurora kinase BHomo sapiens (human)
nucleoplasmAurora kinase BHomo sapiens (human)
spindleAurora kinase BHomo sapiens (human)
cytosolAurora kinase BHomo sapiens (human)
chromocenterAurora kinase BHomo sapiens (human)
microtubule cytoskeletonAurora kinase BHomo sapiens (human)
midbodyAurora kinase BHomo sapiens (human)
chromosome passenger complexAurora kinase BHomo sapiens (human)
mitotic spindle poleAurora kinase BHomo sapiens (human)
mitotic spindle midzoneAurora kinase BHomo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
spindle pole centrosomeAurora kinase BHomo sapiens (human)
spindle microtubuleAurora kinase BHomo sapiens (human)
spindle midzoneAurora kinase BHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 2Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 2Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 2Homo sapiens (human)
cell junctionInositol hexakisphosphate kinase 2Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 2Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (177)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1216683Drug recovery in Sprague-Dawley rat urine assessed as retention time treated with luteolin at 6.5 mg/kg, iv by reverse-phase HPLC method2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1216731Ratio of Vmax(app) to Km(app) for COMT in Sprague-Dawley rat small intestine homogenate assessed per mg protein treated with luteolin up to 10 mins by Michaelis-Menten equation2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1216691Drug metabolism in Sprague-Dawley rat lung homogenate treated with luteolin at 20 uM after 20 to 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1533712Inhibition of human liver microsomes CYP1B1 using Ethoxyresorufin as substrate after 2 mins in presence of NADPH by EROD assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Phytoestrogens and their synthetic analogues as substrate mimic inhibitors of CYP1B1.
AID736341Agonist activity at human PPARdelta expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as beta-galactosidase activity at 50 uM measured after 48 hrs relative to vehicle control2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.
AID1854084Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay2022European journal of medicinal chemistry, Aug-05, Volume: 238The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
AID1162605Inhibition of NF-kappaB signaling in human MDA-MB-231 cells assessed as reduction in PMA-stimulated MMP9 mRNA expression at 25 uM pre-incubated before PMA stimulation by quantitative RT-PCR method relative to untreated control2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Discovery of lesser known flavones as inhibitors of NF-κB signaling in MDA-MB-231 breast cancer cells--A SAR study.
AID427749Inhibition of MRP12009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives.
AID1216715Activity of COMT in Sprague-Dawley rat liver homogenate treated with luteolin up to 10 mins by Michaelis-Menten equation2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1162612Inhibition of NF-kappaB signaling in human MDA-MB-231 cells assessed as reduction in PMA-stimulated MMP9 mRNA expression at 25 uM pre-incubated before PMA stimulation by quantitative RT-PCR method2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Discovery of lesser known flavones as inhibitors of NF-κB signaling in MDA-MB-231 breast cancer cells--A SAR study.
AID439368Agonist activity at human PPARgamma expressed in HEK293 cells co-transfected with PPRE assessed as beta-galactosidase signal at 25 uM after 48 hrs by reporter gene assay relative to control2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
AID400608Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs1996Journal of natural products, Mar, Volume: 59, Issue:3
Ability of different flavonoids to inhibit the procoagulant activity of adherent human monocytes.
AID1434690Inhibition of sucrose loaded POPC/POPE/POPS/PtdIns(3,4,5)P3 (59:20:20:1) liposome binding to eGFP-fused PDK1 PH domain (unknown origin) expressed in Escherichia coli BL21 at 20 uM after 10 mins by fluorescence spectrophotometry based pull down assay relat2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Inhibitory potential of flavonoids on PtdIns(3,4,5)P3 binding with the phosphoinositide-dependent kinase 1 pleckstrin homology domain.
AID404692Inhibition of human salivary alpha-amylase2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Flavonoids for controlling starch digestion: structural requirements for inhibiting human alpha-amylase.
AID1216674Mean residence time (0 to infinity) in Sprague-Dawley rat treated with luteolin at 6.5 mg/kg, iv2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1216726Activity of COMT in Sprague-Dawley rat small intestine homogenate assessed per mg protein treated with luteolin up to 10 mins by Michaelis-Menten equation2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID598342Inhibition of CYP1B1 EROD activity assessed as inhibition of deethylation of 7-ethoxyresorufin to resorufin2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids.
AID1264956Cytotoxicity against human MSC assessed as cell viability at 1 uM treated for 6 days measured on day 7 by alamar blue assay (Rvb = 96 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1572033Inhibition of IP6K2 in [3H]-inositol-labelled HEK293 cells assessed as reduction in insp7 levels at 2.5 uM after 3.5 hrs by HPLC analysis relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis.
AID1216732Ratio of Vmax(app) to Km(app) for COMT in Sprague-Dawley rat erythrocytes homogenate assessed per mg protein treated with luteolin up to 10 mins by Michaelis-Menten equation2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1264957Cytotoxicity against human MSC assessed as cell viability at 5 uM treated for 6 days measured on day 7 by alamar blue assay (Rvb = 96 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1854082Antiproliferative activity against human KBM5 cells assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay2022European journal of medicinal chemistry, Aug-05, Volume: 238The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
AID1572041Inhibition of IPMK in human [3H]-inositol-labelled HCT116 cells assessed as reduction in insp5 levels at 2.5 uM up to 200 mins by HPLC analysis relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis.
AID439372Agonist activity at human PPARalpha expressed in HEK293 cells co-transfected with PPRE assessed as beta-galactosidase signal at 40 uM after 48 hrs by reporter gene assay relative to control2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
AID1162602Inhibition of basal NF-kappaB signaling in human MDA-MB-231 cells assessed as reduction in MMP9 mRNA expression at 25 uM by quantitative RT-PCR method relative to untreated control2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Discovery of lesser known flavones as inhibitors of NF-κB signaling in MDA-MB-231 breast cancer cells--A SAR study.
AID1705065Inhibition of biotinylated 5-(4-((Z)-3-Carboxy-3-hydroxyacryloyl)-4-(4-chlorobenzyl)piperidine-1-carbonyl)-2-((13,35-dioxo-39-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazole-4-yl)-3,6,9,16,19,22,25,28,31-nonaoxa-12,34-diazanonatriacontyl)oxy)benzoi2020European journal of medicinal chemistry, Dec-15, Volume: 208Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors.
AID598381Activity at CYP1A1 in microsomes of human MDA-MB468 cells assessed as parent compound remaining after 20 mins by HPLC analysis2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids.
AID386546Apparent permeability from apical to basolateral side in human Caco-2 cells2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID386552Ratio of permeability from basolateral to apical side over apical to basolateral side in human Caco-2 cells2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID765677Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay2013European journal of medicinal chemistry, Sep, Volume: 67Modulation of human neutrophils' oxidative burst by flavonoids.
AID1452994Inhibition of CYP1B1 (unknown origin)2017European journal of medicinal chemistry, Jul-28, Volume: 135Inhibitors of cytochrome P450 (CYP) 1B1.
AID1216671AUC (0 to t) in Sprague-Dawley rat treated with luteolin at 6.5 mg/kg, iv2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1572030Inhibition of IPMK in human [3H]-inositol-labelled HCT116 cells assessed as reduction in insp5 levels at 10 uM after 3.5 hrs by HPLC analysis relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis.
AID1264954Cytotoxicity against human MSC assessed as cell viability at 5 uM treated for 3 days measured on day 4 by alamar blue assay (Rvb = 97 to 100%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1216685Drug metabolism in Sprague-Dawley rat liver homogenate treated with luteolin at 20 uM after 20 to 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1216730Ratio of Vmax(app) to Km(app) for COMT in Sprague-Dawley rat lung treated with luteolin up to 10 mins by Michaelis-Menten equation2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1264945Induction of osteogenic differentiation in human MSC assessed as increase in ALP activity at 1 uM using p-NPP as substrate after 9 days by colorimetric method relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1216717Activity of COMT in Sprague-Dawley rat lung treated with luteolin up to 10 mins by Michaelis-Menten equation2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1572036Effect on AKT activity in human HCT116 cells assessed as AKT phosphorylation at T308 residues at 2.5 uM after 3 hrs by Western blot analysis2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis.
AID1264949Cytotoxicity against human MSC assessed as decrease in cell number at 1 to 10 uM after 9 days by methylene blue staining based microscopy relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1216700Drug metabolism in Sprague-Dawley rat liver homogenate treated with luteolin at 20 uM after 20 to 60 mins in presence of COMT inhibitor entacapone2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1216728Ratio of Vmax(app) to Km(app) for COMT in Sprague-Dawley rat liver homogenate assessed per mg protein treated with luteolin up to 10 mins by Michaelis-Menten equation2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1162595Inhibition of PMA-stimulated NF-kappaB signaling (unknown origin) expressed in MDA-MB-231 cells at 5 uM incubated for 16 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Discovery of lesser known flavones as inhibitors of NF-κB signaling in MDA-MB-231 breast cancer cells--A SAR study.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID736345Agonist activity at human PPARdelta expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as beta-galactosidase activity at 25 uM measured after 48 hrs relative to vehicle control2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.
AID1566622Inhibition of baker's yeast alpha-glucosidase using p-nitrophenyl alpha-D-glucopyranoside as substrate measured after 30 mins by spectrophotometry analysis2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1572042Inhibition of IP6K2 in human [3H]-inositol-labelled HCT116 cells assessed as reduction in insp7 levels at 2.5 uM after 3.5 hrs by HPLC analysis relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis.
AID1617647Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA
AID201240Minimum inhibitory concentration, that inhibits growth of Staphylococcus aureus in the presence of subinhibitory (30 ug/mL) Berberine2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Flavonolignan and flavone inhibitors of a Staphylococcus aureus multidrug resistance pump: structure-activity relationships.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1288181Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay2016European journal of medicinal chemistry, May-23, Volume: 114Protective effects of kaempferol against reactive oxygen species-induced hemolysis and its antiproliferative activity on human cancer cells.
AID1216727Activity of COMT in Sprague-Dawley rat erythrocytes homogenate assessed per mg protein treated with luteolin up to 10 mins by Michaelis-Menten equation2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID386549Apparent permeability from basolateral to apical side in human Caco-2 cells assessed as drug recovery2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID1264958Cytotoxicity against human MSC assessed as cell viability at 10 uM treated for 6 days measured on day 7 by alamar blue assay (Rvb = 96 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID386541Stability in hank's balanced salt solution at 15 uM after 20 mins2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID1216672AUC (0 to infinity) in Sprague-Dawley rat treated with luteolin at 6.5 mg/kg, iv2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID386542Stability in hank's balanced salt solution at 15 uM after 60 mins2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID765679Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay2013European journal of medicinal chemistry, Sep, Volume: 67Modulation of human neutrophils' oxidative burst by flavonoids.
AID1216676Clearance in Sprague-Dawley rat treated with luteolin at 6.5 mg/kg, iv2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1063901Inhibition of 5-LOX-mediated LTB4 production in human neutrophils using arachidonic acid as substrate at 0.15 to 40 uM preincubated for 10 mins followed by substrate addition measured after 8 mins by enzyme immunoassay relative to control2014European journal of medicinal chemistry, Jan-24, Volume: 72Inhibition of LOX by flavonoids: a structure-activity relationship study.
AID1572026Selectivity ratio of IC50 for human IPMK to IC50 for human IP6K22019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis.
AID439371Agonist activity at human PPARalpha expressed in HEK293 cells co-transfected with PPRE assessed as beta-galactosidase signal at 25 uM after 48 hrs by reporter gene assay relative to control2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
AID386548Apparent permeability from basolateral to apical side in human Caco-2 cells2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID1216694Drug metabolism in Sprague-Dawley rat small intestine homogenate treated with luteolin at 20 uM after 20 to 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1288180Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level by measuring ratio of micromol of quercetin to 100 umol of compound after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay2016European journal of medicinal chemistry, May-23, Volume: 114Protective effects of kaempferol against reactive oxygen species-induced hemolysis and its antiproliferative activity on human cancer cells.
AID1162613Inhibition of NF-kappaB signaling in human MDA-MB-231 cells assessed as reduction in PMA-stimulated COX2 mRNA expression at 25 uM pre-incubated before PMA stimulation by quantitative RT-PCR method2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Discovery of lesser known flavones as inhibitors of NF-κB signaling in MDA-MB-231 breast cancer cells--A SAR study.
AID439367Agonist activity at human PPARgamma expressed in HEK293 cells co-transfected with PPRE assessed as beta-galactosidase signal at 5 uM after 48 hrs by reporter gene assay relative to control2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
AID1264955Cytotoxicity against human MSC assessed as cell viability at 10 uM treated for 3 days measured on day 4 by alamar blue assay (Rvb = 97 to 100%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID598341Inhibition of CYP1A1 EROD activity assessed as inhibition of deethylation of 7-ethoxyresorufin to resorufin2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids.
AID386545Stability in hank's balanced salt solution at 15 uM after 24 hrs2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID386551Apparent permeability across PAMPA membrane assessed as drug recovery2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID386547Apparent permeability from apical to basolateral side in human Caco-2 cells assessed as drug recovery2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID681156TP_TRANSPORTER: drug resistance (SN-38) in BCRP-expressing K562 cells2004Cancer research, Jun-15, Volume: 64, Issue:12
Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
AID1566636Decrease in PTP1B protein expression in CHOK1 cells at 20 uM measured after 48 hrs by Western blot analysis2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1216703Drug metabolism in Sprague-Dawley rat kidney homogenate treated with luteolin at 20 uM after 20 to 60 mins in presence of COMT inhibitor entacapone2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1334870Cytotoxicity against LPS/INF-gamma-stimulated mouse RAW264.7 cells assessed as cell viability at 100 uM by alamar blue assay relative to control2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Structure-activity relationship of the inhibitory effects of flavonoids on nitric oxide production in RAW264.7 cells.
AID502475Inhibition of human CYP1B1 by EROD assay2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Selective inhibition of methoxyflavonoids on human CYP1B1 activity.
AID1566620Inhibition of human recombinant full length PTP1B expressed in Escherichia coli cells at 10 uM using pNPP as substrate preincubated with enzyme for 5 mins followed by incubation with substrate for 10 mins by spectrophotometry analysis relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID386543Stability in hank's balanced salt solution at 15 uM after 120 mins2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID1216725Activity of COMT in Sprague-Dawley rat lung homogenate assessed per mg protein treated with luteolin up to 10 mins by Michaelis-Menten equation2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1572044Inhibition of IPMK in human [3H]-inositol-labelled HCT116 cells assessed as reduction in insp5 levels at 2.5 uM after 3.5 hrs by HPLC analysis relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis.
AID1572043Down regulation of insp5 levels in human [3H]-inositol-labelled HCT116 cells at 2.5 uM after 3.5 hrs by HPLC analysis2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis.
AID1216706Drug metabolism in Sprague-Dawley rat lung homogenate treated with luteolin at 20 uM after 20 to 60 mins in presence of COMT inhibitor entacapone2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1566616Inhibition of PTP1B in CHOK1 cells assessed as increase in phosphorylation of AKT at Ser473 residue at 20 uM measured after 48 hrs by Western blot analysis2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1216723Activity of COMT in Sprague-Dawley rat liver homogenate assessed per mg protein treated with luteolin up to 10 mins by Michaelis-Menten equation2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1572025Inhibition of human IPMK using insP3 as substrate preincubated for 15 mins followed by substrate and measured after 30 mins by TR-FRET assay2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis.
AID1566618Inhibition of human recombinant full length PTP1B expressed in Escherichia coli cells at 1 uM using pNPP as substrate preincubated with enzyme for 5 mins followed by incubation with substrate for 10 mins by spectrophotometry analysis relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1334865Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells by Greiss method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Structure-activity relationship of the inhibitory effects of flavonoids on nitric oxide production in RAW264.7 cells.
AID1264946Induction of osteogenic differentiation in human MSC assessed as increase in ALP activity at 5 uM using p-NPP as substrate after 9 days by colorimetric method relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1216673Mean residence time (0 to t) in Sprague-Dawley rat treated with luteolin at 6.5 mg/kg, iv2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1334867Cytotoxicity against LPS-stimulated mouse RAW264.7 cells assessed as cell viability at 100 uM by alamar blue assay relative to control2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Structure-activity relationship of the inhibitory effects of flavonoids on nitric oxide production in RAW264.7 cells.
AID427750Inhibition of MRP22009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives.
AID1572034Inhibition of IPMK in [3H]-inositol-labelled HEK293 cells assessed as reduction in insp5 levels at 2.5 uM after 3.5 hrs by HPLC analysis relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis.
AID1572039Inhibition of IP6K2 in mouse 3T3-L1 cells assessed as AKT phosphorylation at T308 at 1 uM after 3 hrs by Western blot analysis2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis.
AID1264952Cytotoxicity against human MSC assessed as cell viability at 10 uM measured on day 1 by alamar blue assay (Rvb = 97 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1775659Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay2021Journal of natural products, 03-26, Volume: 84, Issue:3
Sesquiterpenoids from
AID1216697Drug metabolism in Sprague-Dawley rat erythrocytes homogenate treated with luteolin at 20 uM after 20 to 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1264947Induction of osteogenic differentiation in human MSC assessed as increase in ALP activity at 10 uM using p-NPP as substrate after 9 days by colorimetric method relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1216718Activity of COMT in Sprague-Dawley rat small intestine homogenate treated with luteolin up to 10 mins by Michaelis-Menten equation2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1566614Increase in glucose consumption in human HepG2 cells assessed as glucose concentration in the medium treated at 0.4 to 10 uM after incubating cells in the medium containing glucose measured after 24 hrs by glucose oxidase method2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID386550Apparent permeability across PAMPA membrane2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID1216719Activity of COMT in Sprague-Dawley rat erythrocytes homogenate treated with luteolin up to 10 mins by Michaelis-Menten equation2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1216680Drug excretion in Sprague-Dawley rat urine treated with luteolin at 6.5 mg/kg, iv after 24 hrs2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1216716Activity of COMT in Sprague-Dawley rat kidney homogenate treated with luteolin up to 10 mins by Michaelis-Menten equation2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1216709Drug metabolism in Sprague-Dawley rat small intestine homogenate treated with luteolin at 20 uM after 20 to 60 mins in presence of COMT inhibitor entacapone2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1216682Drug excretion in Sprague-Dawley rat urine treated with luteolin at 6.5 mg/kg, iv after 24 hrs co-treated with COMT inhibitor entacapone2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1572031Inhibition of IP6K2 in human [3H]-inositol-labelled HCT116 cells assessed as reduction in insp7 levels at 2.5 uM up to 3.5 hrs by HPLC analysis relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis.
AID1698073Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay
AID1216712Drug metabolism in Sprague-Dawley rat erythrocytes homogenate treated with luteolin at 20 uM after 20 to 60 mins in presence of COMT inhibitor entacapone2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1264953Cytotoxicity against human MSC assessed as cell viability at 1 uM treated for 3 days measured on day 4 by alamar blue assay (Rvb = 97 to 100%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1572037Inhibition of IP6K2 in human HCT116 cells assessed as AKT phosphorylation at T308 at 10 uM after 3 hrs by Western blot analysis2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis.
AID1854083Antiproliferative activity against human KBM5 cells harbouring T315I mutant assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay2022European journal of medicinal chemistry, Aug-05, Volume: 238The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
AID1572029Down regulation of insp5 levels in human [3H]-inositol-labelled HCT116 cells at 10 uM after 3.5 hrs by HPLC analysis2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis.
AID386544Stability in hank's balanced salt solution at 15 uM after 180 mins2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones.
AID598380Activation factor, ratio of IC50 for non-CYP1 expressing human MCF10A to IC50 for CYP1 expressing human MDA-MB-468 cells2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids.
AID765674Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay2013European journal of medicinal chemistry, Sep, Volume: 67Modulation of human neutrophils' oxidative burst by flavonoids.
AID1566617Inhibition of PTP1B in CHOK1 cells assessed as increase in phosphorylation of GSK-3beta at Ser9 residue at 20 uM measured after 48 hrs by Western blot analysis2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1216678Cmax in Sprague-Dawley rat treated with luteolin at 6.5 mg/kg, iv2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1334866Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells by Greiss method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Structure-activity relationship of the inhibitory effects of flavonoids on nitric oxide production in RAW264.7 cells.
AID1700235Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated with enzyme for 10 mins followed by substrate addition and measured after 30 mins by microplate reader analysis2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Potential α-glucosidase inhibitor from Hylotelephium erythrostictum.
AID1264950Cytotoxicity against human MSC assessed as cell viability at 1 uM measured on day 1 by alamar blue assay (Rvb = 97 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID765682Cytotoxicity against human neutrophils assessed as cell viability at 100 uM after 1 hr by trypan blue exclusion assay2013European journal of medicinal chemistry, Sep, Volume: 67Modulation of human neutrophils' oxidative burst by flavonoids.
AID1162607Inhibition of basal NF-kappaB signaling in human MDA-MB-231 cells assessed as reduction in COX2 mRNA expression at 25 uM by quantitative RT-PCR method relative to untreated control2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Discovery of lesser known flavones as inhibitors of NF-κB signaling in MDA-MB-231 breast cancer cells--A SAR study.
AID1216688Drug metabolism in Sprague-Dawley rat kidney homogenate treated with luteolin at 20 uM after 20 to 60 mins2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1216675Half life in Sprague-Dawley rat treated with luteolin at 6.5 mg/kg, iv2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID502474Inhibition of human CYP1A1 by EROD assay2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Selective inhibition of methoxyflavonoids on human CYP1B1 activity.
AID1216724Activity of COMT in Sprague-Dawley rat kidney homogenate assessed per mg protein treated with luteolin up to 10 mins by Michaelis-Menten equation2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1566619Inhibition of human recombinant full length PTP1B expressed in Escherichia coli cells at 5 uM using pNPP as substrate preincubated with enzyme for 5 mins followed by incubation with substrate for 10 mins by spectrophotometry analysis relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1216720Stability in Sprague-Dawley rat liver microsomes at 10 uM after 10 to 30 mins by HPLC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1572024Inhibition of human IP6K2 using insP6 as substrate preincubated for 15 mins followed by substrate and measured after 30 mins by TR-FRET assay2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis.
AID1515260Inhibition of LSD1 (unknown origin) by fluorescence assay2019Bioorganic & medicinal chemistry, 01-15, Volume: 27, Issue:2
Flavone-based natural product agents as new lysine-specific demethylase 1 inhibitors exhibiting cytotoxicity against breast cancer cells in vitro.
AID1775658Inhibition of LPS induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay2021Journal of natural products, 03-26, Volume: 84, Issue:3
Sesquiterpenoids from
AID1572038Activation of AKT activity in mouse 3T3-L1 cells assessed as increase in AKT phosphorylation at T308 residues at 2.5 uM after 3 hrs by Western blot analysis2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis.
AID1264951Cytotoxicity against human MSC assessed as cell viability at 5 uM measured on day 1 by alamar blue assay (Rvb = 97 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1334868Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Structure-activity relationship of the inhibitory effects of flavonoids on nitric oxide production in RAW264.7 cells.
AID1572035Down regulation of insp5 levels in [3H]-inositol-labelled HEK293 cells at 2.5 uM after 3.5 hrs by HPLC analysis2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis.
AID502473Inhibition of human CYP1A2 by EROD assay2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Selective inhibition of methoxyflavonoids on human CYP1B1 activity.
AID1216729Ratio of Vmax(app) to Km(app) for COMT in Sprague-Dawley rat kidney homogenate assessed per mg protein treated with luteolin up to 10 mins by Michaelis-Menten equation2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1216677Volume of distribution in Sprague-Dawley rat treated with luteolin at 6.5 mg/kg, iv2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Role of catechol-O-methyltransferase in the disposition of luteolin in rats.
AID1162608Inhibition of NF-kappaB signaling in human MDA-MB-231 cells assessed as reduction in PMA-stimulated COX2 mRNA expression at 25 uM pre-incubated before PMA stimulation by quantitative RT-PCR method relative to untreated control2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Discovery of lesser known flavones as inhibitors of NF-κB signaling in MDA-MB-231 breast cancer cells--A SAR study.
AID765681Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay2013European journal of medicinal chemistry, Sep, Volume: 67Modulation of human neutrophils' oxidative burst by flavonoids.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1799639Kinase Assay from Article 10.1002/cbic.201000487: \\Biological evaluation and structural determinants of p38u00CEu00B1 mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.\\2010Chembiochem : a European journal of chemical biology, Dec-10, Volume: 11, Issue:18
Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.
AID1801097Aurora B Kinase Assay from Article 10.1111/cbdd.12445: \\Plant-derived flavones as inhibitors of aurora B kinase and their quantitative structure-activity relationships.\\2015Chemical biology & drug design, May, Volume: 85, Issue:5
Plant-derived flavones as inhibitors of aurora B kinase and their quantitative structure-activity relationships.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (185)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.54)18.7374
1990's12 (6.49)18.2507
2000's23 (12.43)29.6817
2010's94 (50.81)24.3611
2020's55 (29.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.40 (24.57)
Research Supply Index5.24 (2.92)
Research Growth Index5.87 (4.65)
Search Engine Demand Index59.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (2.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other182 (97.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]